Want to see JP:2413 full AI Analyst Report?
2413 Stock Chart & Stats
¥1904.50
¥16.00(0.84%)
At close: 4:00 PM EDT
¥1904.50
¥16.00(0.84%)
Day’s Range― - ―
52-Week Range¥1,297.00 - ¥2,746.00
Previous CloseN/A
Volume3.52M
Average Volume (3M)2.99M
Market Cap
¥1.21T
Enterprise Value¥988.19K
Total Cash (Recent Filing)¥156.18B
Total Debt (Recent Filing)¥33.15B
Price to Earnings (P/E)24.6
Beta0.71
Next Earnings
Aug 06, 2026EPS Estimate
20.09Next Dividend Ex-DateN/A
Dividend Yield1.23%
Share Statistics
EPS (TTM)72.52
Shares Outstanding679,124,800
10 Day Avg. Volume2,689,370
30 Day Avg. Volume2,988,500
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.66
Price to Sales (P/S)3.09
P/FCF Ratio17.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,141.43Price Target Upside12.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)81.84
Revenue Forecast (FY)¥393.55B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage (debt-to-equity ~0.08) and steady equity growth provide durable financial flexibility. This reduces refinancing risk, supports investment in product development or M&A, and preserves capacity to weather sector cyclicality common to healthcare services over the next 2–6 months and beyond.
Strong Free Cash Flow GenerationFree cash flow tracking at ~0.89x net income and material improvement in 2026 indicate high cash conversion capacity. Durable FCF supports reinvestment in digital platforms, funds client-facing initiatives, and enables shareholder returns or strategic acquisitions without relying on external financing.
Re-accelerating Revenue And Solid MarginsA 14.5% revenue re-acceleration alongside ~50% gross and ~14% net margins reflects strong demand and sustainable unit economics for its healthcare platforms. This combination supports durable profitability and funds product development, helping maintain competitive positioning in life-sciences services.
Bears Say
Margin Compression Since 2022Reported compression in gross, operating and EBITDA margins relative to 2022–2024 suggests rising costs or a less favorable business mix. If persistent, lower margins can erode the company's ability to reinvest, reduce free-cash-flow elasticity, and constrain long-term margin sustainability.
Uneven Operating Cash ConversionOperating cash flow conversion around 0.70x of net income (and ~0.63x in 2025) highlights variability likely from working-capital timing or receivables. Such inconsistency can limit predictable cash for capex or dividends and increase sensitivity to client payment cycles in the healthcare sector.
ROE Trended Down From Peak LevelsReturns on equity of ~12% are healthy but have declined from exceptional 2022–2023 levels, signaling reduced returns on incremental capital. If this trend persists it could indicate slowing operational efficiency or tougher market dynamics that constrain long-term shareholder return generation.
M3 News
2413 FAQ
What was M3 Inc’s price range in the past 12 months?
M3 Inc lowest stock price was ¥1297.00 and its highest was ¥2746.00 in the past 12 months.
What is M3 Inc’s market cap?
M3 Inc’s market cap is ¥1.21T.
When is M3 Inc’s upcoming earnings report date?
M3 Inc’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were M3 Inc’s earnings last quarter?
M3 Inc released its earnings results on May 01, 2026. The company reported ¥11.11 earnings per share for the quarter, missing the consensus estimate of ¥14.08 by -¥2.97.
Is M3 Inc overvalued?
According to Wall Street analysts M3 Inc’s price is currently Undervalued.
Does M3 Inc pay dividends?
M3 Inc pays a Annually dividend of ¥22 which represents an annual dividend yield of 1.23%. See more information on M3 Inc dividends here
What is M3 Inc’s EPS estimate?
M3 Inc’s EPS estimate is 20.09.
How many shares outstanding does M3 Inc have?
M3 Inc has 679,124,800 shares outstanding.
What happened to M3 Inc’s price movement after its last earnings report?
M3 Inc reported an EPS of ¥11.11 in its last earnings report, missing expectations of ¥14.08. Following the earnings report the stock price went down -0.499%.
Which hedge fund is a major shareholder of M3 Inc?
Currently, no hedge funds are holding shares in JP:2413
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
M3 Inc
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
2413 Stock 12 Month Forecast
Average Price Target
¥2,141.43
▲(12.44% Upside)